PhaseV, a developer of advanced AI/machine learning (ML) solutions to optimise clinical development, has entered into a strategic partnership with Bioforum to enhance the efficiency of clinical trials through advanced AI/ML technology.
This collaboration will see PhaseV’s Trial Optimizer platform integrated into Bioforum’s existing biometric services.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The integration aims to streamline the path from protocol planning to study execution by using AI-powered solutions.
This approach is designed to aid research sponsors in designing, simulating, and optimising complex trials, with the potential to accelerate timelines, reduce costs, and improve success rates while maintaining scientific and regulatory standards.
The Trial Optimizer platform uses AI/ML to quickly simulate and compare numerous trial configurations, enabling sponsors to select the most effective design before patient enrolment begins.
By embedding this technology into Bioforum’s services, the partnership seeks to eliminate expensive handoffs between design and delivery teams and minimise the risk of protocol amendments. This integration is expected to speed up decision-making processes across various therapeutic areas.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBioforum is known for its expertise in biometrics and commitment to data quality and offers a range of services, including data management, biostatistics, statistical programming, and medical writing.
The inclusion of PhaseV’s platform will enhance Bioforum’s capacity to support efficient and high-quality clinical studies. The platform allows for faster iteration, improved statistical confidence, and reduced operational friction, enabling sponsors to conduct optimised trials without additional transition costs.
In a recent obesity study using the Trial Optimizer platform, the required sample size was able to be reduced by approximately 20% while maintaining statistical power.
PhaseV co-founder and CEO Raviv Pryluk said: “As clinical trials become increasingly complex, sponsors are demanding smarter and faster ways to design studies that maximise the probability of success.
“This partnership gives trial sponsors the ability to simulate millions of scenarios and move seamlessly from design to execution without losing time.”
In February 2025, PhaseV partnered with Alimentiv to support the design and execution of adaptive clinical trials focusing on gastrointestinal conditions.
